Clinuvel Pharmaceuticals Management
Management criteria checks 3/4
Clinuvel Pharmaceuticals' CEO is Philippe Wolgen, appointed in Nov 2005, has a tenure of 18.5 years. total yearly compensation is A$6.39M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 6.84% of the company’s shares, worth $33.54M. The average tenure of the management team and the board of directors is 11.7 years and 6.3 years respectively.
Key information
Philippe Wolgen
Chief executive officer
AU$6.4m
Total compensation
| CEO salary percentage | 24.9% |
| CEO tenure | 18.5yrs |
| CEO ownership | 6.8% |
| Management average tenure | 11.7yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | AU$30m |
| Sep 30 2023 | n/a | n/a | AU$30m |
| Jun 30 2023 | AU$6m | AU$2m | AU$31m |
| Mar 31 2023 | n/a | n/a | AU$29m |
| Dec 31 2022 | n/a | n/a | AU$26m |
| Sep 30 2022 | n/a | n/a | AU$24m |
| Jun 30 2022 | AU$7m | AU$1m | AU$21m |
| Mar 31 2022 | n/a | n/a | AU$22m |
| Dec 31 2021 | n/a | n/a | AU$24m |
| Sep 30 2021 | n/a | n/a | AU$24m |
| Jun 30 2021 | AU$5m | AU$2m | AU$25m |
| Mar 31 2021 | n/a | n/a | AU$23m |
| Dec 31 2020 | n/a | n/a | AU$21m |
| Sep 30 2020 | n/a | n/a | AU$18m |
| Jun 30 2020 | AU$3m | AU$2m | AU$15m |
| Mar 31 2020 | n/a | n/a | AU$15m |
| Dec 31 2019 | n/a | n/a | AU$15m |
| Sep 30 2019 | n/a | n/a | AU$16m |
| Jun 30 2019 | AU$1m | AU$894k | AU$18m |
| Mar 31 2019 | n/a | n/a | AU$17m |
| Dec 31 2018 | n/a | n/a | AU$16m |
| Sep 30 2018 | n/a | n/a | AU$15m |
| Jun 30 2018 | AU$2m | AU$818k | AU$13m |
| Mar 31 2018 | n/a | n/a | AU$10m |
| Dec 31 2017 | n/a | n/a | AU$6m |
| Sep 30 2017 | n/a | n/a | AU$7m |
| Jun 30 2017 | AU$2m | AU$787k | AU$7m |
Compensation vs Market: Philippe's total compensation ($USD4.15M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.
CEO
Philippe Wolgen (60 yo)
18.5yrs
Tenure
AU$6,390,101
Compensation
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 18.5yrs | AU$6.39m | 6.84% A$ 33.5m | |
| CFO & Company Secretary | 18.4yrs | AU$3.09m | 0.36% A$ 1.7m | |
| Chief Scientific Officer | 11.7yrs | AU$636.85k | 0.31% A$ 1.5m | |
| Director of Global Operations | no data | no data | no data | |
| Head of Australian Operations & Investor Relations | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data | |
| Head of Quality & Drug Safety | less than a year | no data | no data |
11.7yrs
Average Tenure
Experienced Management: CLVL.Y's management team is seasoned and experienced (11.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 18.6yrs | AU$6.39m | 6.84% A$ 33.5m | |
| Non-Executive Director | 17.3yrs | AU$85.00k | 0.23% A$ 1.1m | |
| Non-Executive Director | 4.7yrs | AU$75.00k | 0.00084% A$ 4.1k | |
| Non-Executive Chairman | 4.5yrs | AU$75.00k | 0.0063% A$ 30.8k | |
| Non-Executive Director | 6.3yrs | AU$75.00k | 0.011% A$ 53.9k |
6.3yrs
Average Tenure
Experienced Board: CLVL.Y's board of directors are considered experienced (6.3 years average tenure).